We claim:

1. A compound which is a cetirizine free species in an amorphous form.

2. The compound of claim 1 having substantially the same X-ray diffraction pattern as shown in Figure 1.

3. The compound of claim 1 having an infrared absorption spectrum comprising absorption bands at about 3414 $cm^{-1}$, about 2828 $cm^{-1}$, about 2459 $cm^{-1}$, about 1159 $cm^{-1}$, and about 1488 $cm^{-1}$.

4. The compound of claim 1 having substantially the same infrared spectrum as shown in Figure 2.

5. The compound of claim 1 having substantially the same differential scanning calorimetry thermogram as shown in Figure 3.

6. A composition comprising cetirizine free species as a solid, wherein at least 80 % by weight of said solid cetirizine is in an amorphous form.

7. The composition of claim 6, wherein at least 95 % of said solid cetirizine is in said amorphous form.

8. The composition of claim 6, wherein at least 99 % of said solid cetirizine is in said amorphous form.

9. The composition of claim 6, which is substantially free of crystalline forms of cetirizine free species.

10. A process for making an amorphous form of cetirizine free species, said process comprising:

a. providing an aqueous solution of a water-soluble form of cetirizine;

b. adjusting the pH of said aqueous solution to a range of from about 5 to about 5.5;

c. contacting said aqueous solution with an extracting solvent selected from the group consisting of dichloromethane, chloroform, dichloroethane, ethyl acetate, methyl acetate and mixtures thereof;

d. distilling off said solvent to form a solid residue; and

e. isolating said solid residue to obtain said amorphous form of cetirizine free species.

11. The process of claim 10, wherein said extracting solvent is dichloromethane.

12. A compound which is the amorphous form of cetirizine free species produced by the process of claim 10.

13. A compound which is the amorphous form of cetirizine free species produced by the process of claim 11.

14. A pharmaceutical composition comprising an amorphous form of cetirizine free species and one or more pharmaceutically acceptable carriers.

15. The pharmaceutical composition of claim 14, further comprising at least one additional active ingredient.

16. The pharmaceutical composition of claim 15, wherein said additional active ingredient is pseudoephedrine.

17. The pharmaceutical composition of claim 15, wherein said additional active ingredient is a leukotriene inhibitor.

18. The pharmaceutical composition of claim 15, wherein said additional active ingredient is an analgesic.

19. A method of treating allergic syndromes, which comprises administering a mammal in need thereof an effective amount of the compound of claim 1.

20. The method of claim 20, wherein said mammal is a human.

21. A process of making cetirizine dihydrochloride which comprises:

a) providing a solid powder which is a cetirizine free species in an amorphous form;

b) contacting said solid powder with a liquid phase containing water; and

c) adding two or more equivalents of hydrochloric acid to said liquid phase so that said cetirizine free species is converted to said cetirizine dihydrochloride.

22. The process of claim 21, further comprising dissolving said solid powder in an organic solvent prior to said contacting step.

23. The process of claim 22, wherein said organic solvent is selected from the group consisting of dichloromethane, chloroform, dichloroethane, ethyl acetate, methyl acetate and mixtures thereof.

24. The process of claim 22, wherein said hydrochloric acid is added in an alcoholic solution.